By Fineline Cube 
Hunan Jiudian Pharmaceutical Co., Ltd. (SHE: 300705) today announced the acquisition of all developed results and intellectual property rights for JIJ02 Gel (formerly “PD‑DP‑008 Gel”) from Chengdu Peide Biopharmaceutical Co., Ltd. The transaction, valued at 90 million yuan, includes a comprehensive technology‑transfer agreement that positions Jiudian to advance the Category 1 chemical drug into Phase 1 clinical trials.
Strategic Rationale
- First‑in‑class Candidate – JIJ02 Gel is specifically designed for acne vulgaris, a condition affecting millions worldwide.
- Reduced Resistance & Superior Safety – Early data suggest lower propensity for drug‑resistance development and an improved safety profile compared with existing topical treatments such as benzoyl peroxide and retinoids.
- Unmet Market Need – No domestic or international product of this class has yet entered the market, offering Jiudian a unique competitive edge.
Transaction Highlights
| Item | Detail |
|---|---|
| Acquiring Company | Jiudian Pharma (SHE: 300705) |
| Target Company | Chengdu Peide Biopharma |
| Asset | JIJ02 Gel (PD‑DP‑008 Gel) – Phase 1 candidate |
| Purchase Price | 90 million yuan |
| Contract | Full technology‑transfer and IP rights |
| Next Milestone | Phase 1 clinical trial initiation (scheduled Q4 2025) |
Market Implications
Jiudian’s acquisition expands its dermatology pipeline and strengthens its position within China’s growing specialty‑pharma sector. The company plans to leverage its manufacturing capabilities and regulatory expertise to accelerate the clinical development timetable and potentially secure early market entry ahead of competitors.
Forward‑Looking Statements
The information in this release contains forward‑looking statements that involve risks and uncertainties. Actual results may differ materially.-Fineline Info & Tech